KRAS and non-small cell lung carcinoma: Similarly, Bodor et al. highlighted that KRAS-mutated NSCLC patients with PD-L1 TPS≥1% had a longer progression-free survival respect to PD-L1 negative patients (4.1 vs. 3.2 months, p  =  0.001) [42].